Outlook Therapeutics Stock Surges After Winning FDA Appeal
Outlook Therapeutics, Inc. (NASDAQ: OTLK) saw its shares jump 50% on Monday after the company secured a major regulatory win — the U.S. Food and Drug Administration granted its appeal following completion of the Formal Dispute Resolution process with the Office of New Drugs.
At the heart of the decision, the FDA concluded that substantial evidence of effectiveness exists for LYTENAVA (bevacizumab-vikg) in treating neovascular age-related macular degeneration. Building on that outcome, the company now plans to resubmit its Biologics License Application in June 2026.
The road to this appeal began after a Type A meeting between Outlook Therapeutics and the Division of Ophthalmology and Office of Specialty Medicine, which followed a Complete Response Letter the FDA issued on December 30, 2025, for the LYTENAVA BLA. Rather than accept the setback, the company pushed back through the formal dispute resolution process — and won.
In its formal response, the Office of New Drugs determined that results from the NORSE TWO trial, supported by confirmatory evidence from NORSE EIGHT alongside natural history, mechanistic, and pharmacodynamic data, collectively establish that LYTENAVA works. The office directed the Division and Office of Specialty Medicine to work directly with Outlook Therapeutics to finalize labeling.
The FDA classified this as a Class 1 resubmission, meaning the agency expects to render a decision within 60 days of receiving the resubmission — a relatively fast timeline that adds further optimism for investors.
Should the FDA approve LYTENAVA, it would become the first ophthalmic formulation of bevacizumab to carry full FDA approval, backed by an FDA-approved manufacturing process, labeling, and pharmacovigilance framework — a milestone that would distinguish it from compounded bevacizumab products currently used off-label in eye care.
For more investor relations information about Outlook Therapeutics, Inc. please visit www.ir.outlooktherapeutics.com.
